Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) has provided an announcement.
China Resources Pharmaceutical Group reported audited consolidated revenue of RMB269.57 billion for 2025, up from RMB257.67 billion a year earlier, with gross profit rising to RMB44.51 billion as it continued to scale its pharmaceutical manufacturing and distribution operations. Net profit attributable to shareholders increased to RMB4.05 billion, while total profit for the year climbed to RMB9.65 billion, indicating improved earnings and operational efficiency that may strengthen its financial position and competitiveness in the Chinese pharmaceutical market.
Other income remained broadly stable and finance costs decreased slightly on a net basis, helping support profitability despite higher selling, distribution and administrative expenses. Earnings per share rose to RMB0.64 from RMB0.53, underscoring enhanced returns for equity holders and signaling a solid year of growth that could reinforce investor confidence in the group’s long-term business trajectory.
The most recent analyst rating on (HK:3320) stock is a Hold with a HK$5.00 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Limited is a Hong Kong–incorporated pharmaceutical company engaged in the production, distribution and retail of medicines and healthcare products across mainland China. The group operates a diversified portfolio spanning prescription drugs, over-the-counter products and pharmaceutical distribution services, positioning it as a major player in China’s healthcare supply chain.
Average Trading Volume: 9,985,830
Technical Sentiment Signal: Sell
Current Market Cap: HK$27.83B
For a thorough assessment of 3320 stock, go to TipRanks’ Stock Analysis page.